4 Reasons Pfizer Could Be a Value Play You Can’t Miss BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a restructuring of its…
nufacturing network. Chairman of the Supervisory Board Helmut Jeggle said the 2025 fiscal year was “a successful one” for the company, citing progress toward BioNTech’s goal of becoming a multi-product company by 2030
He said the company ended 2025 with cash and marketable securities totaling EUR 17.2 billion, giving it “substantial resources” for its next phase of development. Management Highlights Oncology Pipeline and BMS Partnership – Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze? Chief Executive Officer Professor Dr.
Ugur Sahin, delivering what he described as his final annual general meeting address as CEO, said BioNTech’s strategy remains focused on two pillars: maintaining its COVID-19 vaccine business with partner Pfizer and using proceeds to advance a diversified development pipeline, particularly in oncology. Sahin said BioNTech and Pfizer have delivered more than 5 billion COVID-19 vaccine doses worldwide since 2020. He added that BioNTech’s vaccine is distributed in more than 180 countries and regions and has a market share of more than 50% in key markets. – Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?